Prostate cancer vaccines: Current status

L. C. Hwang, S. Fein, H. Levitsky, W. G. Nelson

Research output: Contribution to journalReview articlepeer-review

Abstract

Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passive immunotherapy with monoclonal antibodies, adoptive transfer of activated effector T cells, and active immunotherapy involving immunization with whole-cell or antigen-specific vaccines. These therapies are being modified with cytokines and other immune modulating agents. Understanding the mechanisms of antitumor immunity and identifying relevant tumor-specific antigens will likely improve these vaccine strategies and provide them with a niche in the future of prostate cancer therapy.

Original languageEnglish (US)
Pages (from-to)192-201
Number of pages10
JournalSeminars in oncology
Volume26
Issue number2
StatePublished - May 18 1999
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Prostate cancer vaccines: Current status'. Together they form a unique fingerprint.

Cite this